This company listing is no longer active
B1N Stock Overview
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bionomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.007 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.0024 |
| Beta | 1.75 |
| 1 Month Change | 191.67% |
| 3 Month Change | 25.00% |
| 1 Year Change | -76.67% |
| 3 Year Change | -94.17% |
| 5 Year Change | -97.67% |
| Change since IPO | -91.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| B1N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -76.7% | -19.9% | 0.9% |
Return vs Industry: B1N underperformed the German Biotechs industry which returned -3.1% over the past year.
Return vs Market: B1N underperformed the German Market which returned 12.1% over the past year.
Price Volatility
| B1N volatility | |
|---|---|
| B1N Average Weekly Movement | 83.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B1N's share price has been volatile over the past 3 months.
Volatility Over Time: B1N's weekly volatility has increased from 59% to 83% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spyros Papapetropoulos | www.bionomics.com.au |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Bionomics Limited Fundamentals Summary
| B1N fundamental statistics | |
|---|---|
| Market cap | €6.40m |
| Earnings (TTM) | -€14.88m |
| Revenue (TTM) | €3.59m |
1.8x
P/S Ratio-0.4x
P/E RatioIs B1N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B1N income statement (TTM) | |
|---|---|
| Revenue | AU$6.02m |
| Cost of Revenue | AU$19.80m |
| Gross Profit | -AU$13.79m |
| Other Expenses | AU$11.13m |
| Earnings | -AU$24.91m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | -229.04% |
| Net Profit Margin | -413.94% |
| Debt/Equity Ratio | 0% |
How did B1N perform over the long term?
See historical performance and comparison